▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

89bio (NASDAQ: ETNB)

$9.62

(-4.2%)

-$0.42

Price as of June 12, 2025, 4:00 p.m. ET

89bio Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
ETNB	+1.69%	-60.36%	-16.89%	-52%
S&P	+11.51%	+98.77%	+14.72%	+96%

89bio Company Info

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

News & Analysis

Featured Article

Why 89bio Stock Lagged the Market Today

Eric Volkman | Jan 28, 2025

Featured Article

Why Shares of 89bio Plummeted on Tuesday

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

Jim Halley | Oct 10, 2023

3 Biotech Buyout Targets to Watch

Jim Halley | Apr 29, 2023

The trio all have late-stage therapies with blockbuster potential.

Why Shares of 89bio Soared This Week

Jim Halley | Mar 24, 2023

The company released positive results for its lead therapy.

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services